Journal Thoracic Oncology

Abstracts Journal of Thoracic Oncology • Volume 12 Issue S1 January 2017
pain, and another developed grade 3 chest wall pain. Therefore 50 Gy was
determined to be the MTD. On PRO-CTCAE questionnaires patients most
frequently reported fatigue (75%), dyspnea (50%), cough (38%), and pain
(38%) as interfering “quite a bit” or “very much” with their daily activities.
Conclusion: We determined that 50 Gy in five fractions followed by sequential
chemotherapy is the MTD for SBRT in patients with stage IIA to IIIA NSCLC.
Long-term outcomes and larger trials will be needed to assess whether
SBRT results in superior local control and survival compared to conventional
chemoradiation. Made possible by the generous support of the DallePezze
Foundation
Keywords: Locally advanced NSCLC, stereotactic body radiation therapy
(SBRT)
POSTER SESSION 2 – P2.02: LOCALLY ADVANCED NSCLC
Toxicities –
TUESDAY, DECEMBER 6, 2016
P2.02-061 ROLE OF MMP-2-1306C/T IN ONSET OF HEMATOLOGICAL
TOXICITY IN LUNG CANCER PATIENTS RECEIVING FIRST LINE
PLATINUM BASED THERAPY
Antonella Daniele 1 , Rosa Divella 2 , Domenico Galetta 1 , Ines Abbate 2 , Porzia
Casamassima 2 , Antonio Fabio Logroscino 1 , Elisabetta Sara Montagna 1 ,
Annamaria Catino 1
1 National Cancer Research Centre, Istituto Tumori “Giovanni Paolo Ii” Bari, Italy,
Bari/Italy, 2 1National Cancer Research Centre, Istituto Tumori “Giovanni Paolo Ii”
Bari, Italy, Bari/Italy
Background: Lung cancer is the most common and lethal cancer worldwide.
Totally, about 85% of lung cancer cases could be classified as Non-Small Cell
Lung Cancer (NSCLC) and most are diagnosed at advanced stage. Matrix
Metalloproteinases are a family of zinc endopeptidases with proteolytic
activity against the extracellular matrix components playing a key role
in the process of tumor growth/metastasis. Genetic variants in matrix
metalloproteinase-2 (MMP-2) gene may influence the biological function of
this enzyme changing his role in carcinogenesis, hematopoietic recovery from
chemotherapy toxicity and cancer progression. This study has investigated
the association of single nucleotide polymorphism (-1306C/T) in the MMP-2
promoter sequence, and the link with a strong hematological toxicity in lung
cancer patients receiving first-line, platinum-based chemotherapy. Methods:
Forthy-seven patients (36 men and 9 women) with IIIA/IV NSCLC stage
were enrolled; information about hematologic toxicity (thrombocytopenia,
neutropenia, anemia), gastrointestinal toxicity (nausea/vomiting), and
smoking habits were collected through the clinical charts. Genotyping was
performed using direct DNA sequencing. Results: 25/47 patients (53%) had
the CC genotype, 8/47 (17%) patients had CT genotype and 14/47 (30%) had
TT genotype. A grade 2-3 anemia associated to grade 2-3 thrombocytopenia
and/or G2-3 neutropenia was observed in 12/22 CC patients compared with
only 4/14 TT patients and 3/8 CT patients (p250cGy). We observed as well that
patients who developed pneumonitis had more often central and lower
tumors, and percentage of irradiated lung with 20Gy greater than 35% (PA
V20>35%) and 5Gy over 65% (PA V5>65%). PFTs alterations prior to treatment
that identified the development of severe pneumonitis included: a lower
forced expiratory volume in one second after bronchodilator (FEV1, p=